Who is Vas Narasimhan, the Indian-origin Novartis CEO who joined Anthropic's board

Anthropic, a prominent American AI firm known for its Claude AI models, has welcomed Vasant Narasimhan, often referred to as Vas, to its board of directors. As the first healthcare executive to join the board, Narasimhan's appointment signifies Anthropic's commitment to integrating artificial intelligence into pharmaceuticals and medical innovation. Currently serving as the CEO of Novartis, a leading Swiss pharmaceutical company since 2018, Narasimhan expressed his enthusiasm for the new role. He emphasized the importance of responsible technology deployment, which resonates with Anthropic's mission to develop safe AI systems. "My experience in medicine and global health has highlighted the transformative potential of technology when used ethically. In the healthcare sector, AI is paving the way for solutions to complex scientific issues, from enhancing our understanding of diseases to creating more effective medications," Narasimhan stated. Joining Narasimhan on the board are notable figures including Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell, all of whom bring diverse expertise to the table. Narasimhan's journey began with a focus on biological sciences at the University of Chicago, followed by earning both an MD and a Master's in Public Policy from Harvard's Kennedy School. Before ascending to leadership roles at Novartis, he dedicated his early career to tackling healthcare challenges in some of the world's most disadvantaged areas, spearheading initiatives against HIV/AIDS, malaria, and tuberculosis across regions such as India, Africa, and South America. His influence stretches beyond the pharmaceutical industry; Narasimhan is a member of the US National Academy of Medicine and is involved with the Council on Foreign Relations. He also holds trustee positions at the University of Chicago and is a fellow on the board of Harvard Medical School. Previously, he chaired PhRMA, a significant pharmaceutical industry organization in Washington, D.C., and continues to serve on its board, further cementing his role in shaping healthcare through innovation.